Instrument Inactif

Communiqués Silence Therapeutics plc London S.E.

Actions

SLN

GB00B9GTXM62

Recherche biotechnologique et médicale

Communiqués

11/06	Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera	BU
27/05	Silence Therapeutics to Participate in Jefferies Global Healthcare Conference	BU
12/05	Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference	BU
07/05	Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results	BU
05/03	Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results	BU
15/12	Silence Therapeutics Announces Leadership Changes	BU
12/11	Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference	BU
06/11	Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights	BU
24/10/25	Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera	AQ
23/10/25	Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)	BU
02/09/25	Silence Therapeutics to Participate in September Investor Conferences	BU
07/08/25	Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights	BU
12/06/25	Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera	BU
08/05/25	Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights	BU
06/05/25	Silence Therapeutics Welcomes Tim McInerney to Board of Directors	BU
05/03/25	Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference	BU
27/02/25	Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update	BU
13/02/25	Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025	BU
02/01/25	Silence Therapeutics : Regulation FD Disclosure Form 8 K	PU
09/12/24	Silence Therapeutics : also announces first subject dosed in Phase 2 study of divesiran in PV patients Company reinforces commitment to prioritize divesiran development as the first in class siRNA in PV Form 6 K	PU
09/12/24	Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting	BU
26/11/24	Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference	BU
18/11/24	Silence Therapeutics : New zerlasiran data show significant time averaged Lp(a) reductions with effects persisting 60 weeks following the first dose Represents first study to report time averaged Lp(a) results to further evaluate potential clinical benefits Data simultaneously published in the Journal of the American Medical Association Form 6 K	PU
18/11/24	Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting	BU
14/11/24	Silence Therapeutics : Condensed consolidated income statement (unaudited) Form 6 K	PU